Latest Commercialization News

Saferoads Holdings reports a modest quarterly profit driven by cost cuts and prepares to settle the sale of its Road Safety Rentals business, aiming to clear debt and refocus on product sales growth.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

Empire Energy Group is advancing its Carpentaria-5H well hydraulic stimulation scheduled for June 2025, alongside preparations for the Carpentaria Gas Plant construction, aiming to commence gas sales from EP187 by late 2025 or early 2026.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Blue Energy has resolved a significant legal hurdle by securing an amended Environmental Authority for its Sapphire asset, enabling progression of the Petroleum Lease 1034 and continued pilot production testing despite operational interruptions.

Austral Gold’s Q1 2025 report reveals a 15.4% drop in gold equivalent production at its Guanaco mine due to mine depletion and mill repairs, while refurbishment advances at Casposo aim to boost future output.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

QPM Energy Limited has announced a significant 31% upgrade to its Moranbah Gas Project's 2P reserves, now certified at 435PJ, reinforcing the asset's status as a tier 1 gas resource with substantial uncontracted volumes.

Alpha HPA Limited reports significant progress on its HPA First Project Stage 2 with key infrastructure completed and engineering milestones met. Strong semiconductor sector demand drives Letters of Intent covering over 60% of Stage 2 production, while sapphire wafer production and leadership changes position the company for growth.